By the end of 2022, the global diabetic macular edema market size is predicted to be valued US$ 3.7 billion. From 2022 to 2032, it is projected to grow at a compound annual growth rate (CAGR) of 1.2%. By the end of 2032, the market is expected to be valued at approximately US$ 4.2 billion.
As the current standard of care for DME, anti-VEGF medications are anticipated to maintain their market dominance throughout the forecast period. However, novel treatments like gene therapy and bispecific antibodies are just starting to gain traction and are predicted to overtake existing treatments in the years to come.
Request A Sample Copy of This Report! https://www.futuremarketinsights.com/reports/sample/rep-gb-2697
North America is the largest market for DME treatment, followed by Europe and Asia Pacific. The North American market is expected to remain dominant during the forecast period, due to the high prevalence of diabetes and DME in the region.
An Uptake of Intravitreal Implants by Patients to Drive Growth of the Market in North America:
North America will remain dominant in the global diabetic macular edema market. An uptake of intravitreal implants by new as well as existing patients, who do not show any improvement post-treatment with intravitreal injections, is expected to sustain growth of the market in this region.
Although control of diabetes is a health priority in developed North American countries, such as the U.S., less attention is given to DME management, with diabetes-related caregivers tending to focus on treatment of diabetic complications. A major reason behind this is lack of effective treatment for DME in North America. In addition, an error exists between industry sponsored and independently run clinical trials. Most of the independent clinical trials for DME treatment lack long-term results pertaining to safety and efficacy of new combination therapies for DME. These factors are likely to inhibit growth of the market in North America.
Diabetic Macular Edema Market in Western Europe to Register the Highest CAGR:
The diabetic macular edema market in Western Europe is expected to register a comparatively higher CAGR than other region segments through 2027. Pharmaceutical companies in this region are making substantial investments in research and development, new technologies, and infrastructure in order to capture a market share in the surging burden of eye diseases. This is expected to retain growth of the market in Western Europe.
However, patients in Western Europe resist the intake of intravitreal injections of anti-VEGF drugs, which leads to an instant increase in intraocular pressure causing severe pain in the head or eyes. This a major factor impeding growth of the diabetic macular edema market in Western Europe.
Connect With Our Analyst To Address Any Inquiries You May Have! https://www.futuremarketinsights.com/ask-question/rep-gb-2697
Anti-VEGF will Remain Preferred Product in the Global Diabetic Macular Edema Market:
Anti-VEGF will remain preferred product in the market, with sales estimated to expand at 1% CAGR through 2027. Eylea will continue to be the most lucrative anti-VEGF drug in the market. However, demand for corticosteroids will remain comparatively lower than anti-VEGF during the forecast period.
By product form, intravitreal injections will continue to be sought-after in the market, with sales poised to surpass US$ 4,000 Mn by 2027-end. Sales of intravitreal implants will register a comparatively higher CAGR than intravitreal injections through 2027.
Hospital pharmacy is estimated to remain the largest distribution channel in the market, as majority of countries across the globe dispense intravitreal injections and implants to outpatients by hospital pharmacies. Retail pharmacy, which mainly provides aliquots of off-label indications such as Avastin prescription, will register a comparatively low CAGR than hospital pharmacy in the market through 2027.
Key market players identified in FMI’s report include Novartis AG, Bayer AG, Allergan Plc., F. Hoffman-La Roche Ltd., Alimera Sciences Inc., Valeant Pharmaceuticals International, Inc. (Bausch & Lomb Inc.)
Empower Your Business with Customization: Discover the Strategies in Our New Report! https://www.futuremarketinsights.com/customization-available/rep-gb-2697
Key Segments Covered In Diabetic Macular Edema Market Report:
By Drug:
- Anti-VEGF
- Ranibizumab (Lucentis)
- Aflibercept (Eylea)
- Corticosteroid Therapies
- Dexamethasone (Ozurdex)
- Fluocinolone Acetonide (Iluvien)
- Other Off-label Drugs
By Form:
- Intravitreal Injections
- Intravitreal Implants
By Distribution Channel:
- Hospitals
- Specialty Clinics
- Mail Order Pharmacies
To Available Discount on Report, Click! https://www.futuremarketinsights.com/checkout/2697
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
